Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: final results of a prospective phase II study.

[1]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  P. Macaskill,et al.  Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. , 2012, European journal of cancer.

[3]  V. Valentini,et al.  Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: a prospective phase II study. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  G. Hortobagyi,et al.  Anthracyclines in the Treatment of Cancer , 2012, Drugs.

[5]  L. Bonomo,et al.  MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer. , 2012, The British journal of radiology.

[6]  V. Valentini,et al.  A Feasibility Study of Neo-Adjuvant Low-Dose Fractionated Radiotherapy with Two Different Concurrent Anthracycline-Docetaxel Schedules in Stage IIA/B-IIIA Breast Cancer , 2012, Tumori.

[7]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  A. Luini,et al.  Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. , 2011, Breast.

[9]  M. Mohiuddin,et al.  Low-Dose Fractionated Radiation Potentiates the Effects of Cisplatin Independent of the Hyper-Radiation Sensitivity in Human Lung Cancer Cells , 2011, Molecular Cancer Therapeutics.

[10]  C. Rödel,et al.  Discontinuous induction of X-linked inhibitor of apoptosis in EA.hy.926 endothelial cells is linked to NF-κB activation and mediates the anti-inflammatory properties of low-dose ionising-radiation. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Baljit Singh,et al.  Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival , 2010, Breast Cancer Research and Treatment.

[12]  S. Mocellin,et al.  Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer. , 2010, Anticancer research.

[13]  J. Yarnold,et al.  Target volume definition for external beam partial breast radiotherapy: clinical, pathological and technical studies informing current approaches. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  V. Valentini,et al.  Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings? , 2010, International journal of radiation oncology, biology, physics.

[15]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Baselga,et al.  Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  V. Catalano,et al.  Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer , 2008, Anti-cancer drugs.

[18]  B. Marples,et al.  Low-dose hyper-radiosensitivity: past, present, and future. , 2008, International journal of radiation oncology, biology, physics.

[19]  E. Winer,et al.  Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Mansoor M Ahmed,et al.  Lack of P-Glycoprotein Expression by Low-Dose Fractionated Radiation Results from Loss of Nuclear Factor-κB and NF-Y Activation in Oral Carcinoma Cells , 2008, Molecular Cancer Research.

[22]  A. Schneeweiss,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Greil,et al.  Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Tan,et al.  Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. , 2007, International journal of radiation oncology, biology, physics.

[26]  M. Mouret-Reynier,et al.  Indications, contre-indications, résultats attendus et choix de la chimiothérapie néoadjuvante du cancer du sein opérable , 2006 .

[27]  S. Feldman,et al.  Primary systemic therapy of breast cancer. , 2006, The oncologist.

[28]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Billheimer,et al.  Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer , 2006, Clinical Cancer Research.

[30]  J. Blohmer,et al.  Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Blohmer,et al.  Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial , 2005, Anti-cancer drugs.

[32]  W. Regine,et al.  Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. , 2004, International journal of radiation oncology, biology, physics.

[33]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Mansoor M Ahmed,et al.  Low Dose Fractionated Radiation Potentiates the Effects of Taxotere in Nude Mice Xenografts of Squamous Cell Carcinoma of Head and Neck , 2004, Cell cycle.

[35]  S. Campos.  Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. , 2003, The oncologist.

[36]  W. Regine,et al.  Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  E. Perez,et al.  Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  H. Gogas,et al.  Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  I. Barillot,et al.  Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. , 2001, The New England journal of medicine.

[40]  G. Döring,et al.  Sepsis in a newborn due to Pseudomonas aeruginosa from a contaminated tub bath. , 2001, The New England journal of medicine.

[41]  G. Batist,et al.  Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  P Lambin,et al.  Low-dose hypersensitivity: current status and possible mechanisms. , 2001, International journal of radiation oncology, biology, physics.

[43]  Mansoor M Ahmed,et al.  Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53. , 2000 .

[44]  J. Bellon,et al.  Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. , 2000, International journal of radiation oncology, biology, physics.

[45]  T. Whelan,et al.  Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  H. Silberman,et al.  Preoperative Paclitaxel and Radiotherapy for Locally Advanced Breast Cancer: Surgical Aspects , 2000, Annals of Surgical Oncology.

[47]  L. Milas,et al.  Docetaxel enhances tumor radioresponse in vivo. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  E. Touboul,et al.  Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer. , 1996, International journal of radiation oncology, biology, physics.

[49]  Deepinder P. Singh,et al.  Neoadjuvant chemotherapy in locally advanced breast cancer , 1996, Journal of surgical oncology.

[50]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[51]  G. Calais,et al.  Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm , 1994, Cancer.

[52]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[53]  M. Piccart,et al.  Systemic treatment for locally advanced breast cancer: what we still need to learn after a decade of multimodality clinical trials. , 1992, European journal of cancer.

[54]  B. Marples,et al.  Exposure to low dose ionising radiation: Molecular and clinical consequences. , 2014, Cancer letters.

[55]  A. Fiorentino,et al.  Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. , 2012, Neuro-oncology.

[56]  H. Iwase,et al.  Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin–docetaxel neoadjuvant chemotherapy: a cohort study , 2009, Breast cancer.

[57]  F. Penault-Llorca,et al.  High Prognostic Significance of Residual Disease After Neoadjuvant Chemotherapy: a Retrospective Study in 710 Patients with Operable Breast Cancer , 2006, Breast Cancer Research and Treatment.

[58]  M. Mouret-Reynier,et al.  [Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer]. , 2006, Bulletin du cancer.

[59]  S. Haga,et al.  Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer , 2003, Breast cancer.

[60]  Lyndsay Harris,et al.  Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.

[61]  P. Lambin,et al.  Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells. , 1997, International journal of radiation biology.

[62]  M. Zwahlen,et al.  Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients (Review) , 2022 .